Urocentrum Praha s.r.o.

Clinical trials at this Prague site focus strongly on prostate cancer, especially advanced and treatment-resistant forms. The research is centered on testing new treatment combinations and comparing them with current standards to improve disease control and delay progression.

• Studies in metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer
• Research in high-risk recurrent prostate cancer and non-metastatic disease with risk of spread
• Evaluation of novel hormonal, targeted, and combination therapies for better cancer control

The site contributes to studies aimed at improving survival outcomes, slowing progression, and refining treatment choices for men with advanced prostate cancer.

This research area includes trials that compare investigational medicines with established therapies to see whether they can better delay radiographic progression or extend metastasis-free survival. The work is focused on patients whose disease has become resistant to standard hormone-based treatment.

• Testing new approaches for PTEN-deficient metastatic hormone-sensitive prostate cancer
• Comparing olaparib-based and abiraterone-based strategies in advanced disease
• Assessing whether newer agents can improve outcomes in castration-resistant prostate cancer

These studies are designed to improve treatment effectiveness and help identify which patients may benefit most from precision oncology approaches.

Another major theme at Urocentrum Praha s.r.o. is evaluating therapies that combine different treatment types to better manage metastatic prostate cancer. The trials explore whether adding a new drug or treatment modality can slow progression, reduce spread, or improve survival compared with standard care.

• Studies of apalutamide alongside radiotherapy and hormone therapy
• Research on radium-223 dichloride for cancer that has spread to the bone
• Trials of combined cabozantinib and atezolizumab strategies

This field reflects a broader effort to improve outcomes through multimodal cancer treatment and to better understand how advanced therapies perform in real patients.

The site’s trial portfolio also touches on broader reproductive and urinary physiological phenomena, with a clear emphasis on cancers affecting the prostate. These studies aim to clarify how disease behaves over time and whether newer medicines can delay worsening in men with limited treatment options.

• Investigation of treatments for metastatic castration-resistant prostate cancer after prior hormone therapy
• Assessment of therapies for men with metastatic castration-sensitive prostate cancer
• Research into disease progression and response in advanced uro-oncology

Overall, the research supports better decision-making in oncology by comparing emerging therapies with current standards and tracking their effect on progression and survival.